2022
Clinical Phenotypes of Immediate First-Dose Reactions to mRNA COVID-19: A Multicenter Latent Class Analysis
Stone CA, Robinson LB, Li L, Krantz MS, Kwah JH, Ortega G, Mancini C, Wolfson AR, Saff RR, Samarakoon U, Hong DI, Koo G, Chow TG, Gruchalla R, Liao JX, Kuster JK, Price C, Ahola C, Khan DA, Phillips EJ, Banerji A, Blumenthal KG. Clinical Phenotypes of Immediate First-Dose Reactions to mRNA COVID-19: A Multicenter Latent Class Analysis. The Journal Of Allergy And Clinical Immunology In Practice 2022, 11: 458-465.e1. PMID: 36108922, PMCID: PMC9468049, DOI: 10.1016/j.jaip.2022.08.048.Peer-Reviewed Original ResearchConceptsMRNA COVID-19 vaccineNovel clinical phenotypesCOVID-19 vaccineDose 1Second doseClinical phenotypeObjective signsLatent class analysisMRNA coronavirus disease 2019 (COVID-19) vaccinesDose toleranceAllergy/immunology specialistsMRNA COVID-19 vaccinationCoronavirus disease 2019 (COVID-19) vaccinesSelf-limiting symptomsFirst-dose reactionsU.S. academic medical centersLog-binomial regressionCOVID-19 vaccinationDistinct clinical phenotypesAcademic medical centerImmediate reactionsImmunology specialistsClass analysisAllergic symptomsRetrospective study
2021
Safety Evaluation of the Second Dose of Messenger RNA COVID-19 Vaccines in Patients With Immediate Reactions to the First Dose
Krantz MS, Kwah JH, Stone CA, Phillips EJ, Ortega G, Banerji A, Blumenthal KG. Safety Evaluation of the Second Dose of Messenger RNA COVID-19 Vaccines in Patients With Immediate Reactions to the First Dose. JAMA Internal Medicine 2021, 181: 1530-1533. PMID: 34309623, PMCID: PMC8314170, DOI: 10.1001/jamainternmed.2021.3779.Peer-Reviewed Original Research